Avoiding or Controlling Diabetes May Reduce Cancer Risk and Mortality
http://www.aacr.org/home/public--media/aacr-in-the-news.aspx?d=2324
April 3, 2011
• Diabetes linked to an 11 percent increased risk for cancer mortality in women; 17 percent increased risk in men.
• Increased risk for colon, rectum and liver cancer in men and women.
• Associations appear to be independent of other cancer risk factors.
ORLANDO, Fla. — Results of the NIH-AARP Diet and Health Study revealed that diabetes is associated with lower risk of prostate cancer in men but with higher risk of other cancers in both men and women. The data, to be presented at the AACR 102nd Annual Meeting 2011, held here April 2-6, also showed an association between diabetes and higher cancer mortality rates.
Previous epidemiologic studies have shown an association between diabetes and an increased risk for cancers including colorectal, liver and pancreas, according to Gabriel Lai, Ph.D., a cancer prevention fellow at the National Cancer Institute.
“Our results provide further evidence that abnormal insulin and glucose signaling may contribute to cancer initiation and development,” he said. “There are myriad benefits from avoiding diabetes through exercise, diet and maintaining a healthy body weight. Our study confirms additional benefits in the form of reduced morbidity and mortality from certain cancers.”
Lai and colleagues conducted a prospective study using data from more than 500,000 predominantly white, non-Hispanic men and women aged 50 to 71 years. From 1995 to 1996, the participants completed questionnaires about diet, lifestyle and whether or not they had diabetes. Researchers followed the patients for 11 years.
Results showed that diabetes was associated with an 8 percent increased risk for cancer among women and a 4 percent decreased risk for men. In previous research, a decreased risk for prostate cancer was associated with diabetes, which researchers believe might be due to the lower testosterone levels associated with diabetes. After excluding prostate cancer from their evaluation, Lai and colleagues found that diabetes was associated with a 9 percent increased risk for cancer in men.
As for mortality, diabetes was associated with an 11 percent increased risk in women and a 17 percent increased risk in men.
“These risks appeared independent from other cancer risk factors, such as obesity and cigarette smoking,” Lai said.
After evaluating by cancer site, the researchers found diabetes was associated with a significant increase in risk for colon, rectal and liver cancers among men and women. In men, diabetes was associated with an increased risk for pancreatic and kidney cancers; in women, it was associated with an increased risk for stomach, anal and endometrial cancers. No association was found between diabetes and lung, skin or other cancers.
“Follow-up studies to identify the biologic mechanisms involved should be performed to build upon confirmed findings,” Lai said.
# # #
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.
Media Contact:
Jeremy Moore
(267) 646-0557
Jeremy.Moore@aacr.org
In Orlando, April 2-6:
(407) 685-4001
< Back to AACR in the News
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment